NCT07642908 Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
| NCT ID | NCT07642908 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-09-18 |
| Primary Completion | 2026-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2025-09-18 with a primary completion date of 2026-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.
Eligibility Criteria
Inclusion Criteria: 1. Male or Female, age 45 years and over. 2. Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992). 3. Presence of LRRK2 mutation as confirmed by referral from UM Movement Disorders clinic, medical record review, or participation in the PDGENEration study. Exclusion Criteria: 1. Evidence of atypical parkinsonism. 2. Contra-indications to MR imaging including but not limited to pacemakers, aneurysm clips, intraocular metal, cochlear implant, or severe claustrophobia. 3. Evidence of large vessel stroke or mass lesion on MRI. 4. Regular use of typical anti-cholinergic drugs or cholinesterase inhibitors. 5. History of deep brain stimulation surgery. 6. Pregnant or nursing. 7. Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. 8. Cognitive impairment that results in the inability to give consent, as demonstrated by the Decision Making Capacity Tool. 9. Any other condition or criterion that would preclude safe and meaningful participation in the study.
Contact & Investigator
Prabesh Kanel, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07642908 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07642908 currently recruiting?
Yes, NCT07642908 is actively recruiting participants. Contact the research team at natealex@med.umich.edu for enrollment information.
Where is the NCT07642908 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07642908 clinical trial?
NCT07642908 is sponsored by University of Michigan. The principal investigator is Prabesh Kanel, PhD at University of Michigan. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.